Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 11/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472940 | 0.85 | CYP2C9 (0.41) | MAPK1MEN1KMT2A | |
| SCHEMBL22472870 | 0.83 | CYP11B1 (0.35) | CHRM1LMNATP53TDP1POLB | |
| SCHEMBL22449320 | 0.82 | CHRM1 (0.40) | CHRM1LMNAPOLBMAPK1MEN1 | |
| SCHEMBL22472866 | 0.78 | LMNA (0.36) | CHRM1LMNATP53POLBMAPK1 | |
| SCHEMBL22472893 | 0.75 | CHRM1 (0.31) | CHRM1LMNATP53POLBMAPK1 | |
| SCHEMBL22472944 | 0.74 | CHRM1 (0.67) | CHRM1 | |
| SCHEMBL22472934 | 0.73 | CHRM1 (0.34) | CHRM1TP53TDP1 | |
| SCHEMBL22472905 | 0.73 | ALDH1A1 (0.53) | CHRM1LMNAPOLBMAPK1MEN1 | |
| SCHEMBL22472884 | 0.71 | CHRM1 (0.46) | CHRM1LMNAMEN1RAB9AKMT2A | |
| SCHEMBL21138360 | 0.70 | TSHR (0.55) | LMNATDP1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885LMNA 3439/4885TP53 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.